This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit (MOVE-IT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2010 by St. John Health System, Michigan.
Recruitment status was:  Recruiting
Information provided by:
St. John Health System, Michigan Identifier:
First received: January 13, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted
The purpose of this study is to determine if there will be a significantly higher incidence of a bowel movement with methylnaltrexone vs. placebo within 4 hours +- 45 minutes with decreased need for rescue medications in the intensive care unit in patients with opioid-induced constipation. Patients will also be managed with an aggressive bowel management protocol.

Condition Intervention Phase
Opioid-induced Constipation Drug: Methylnaltrexone Bromide Drug: Placebo-Normal Saline Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Methylnaltrexone for the Reversal of Opiate-Induced Constipation in the Intensive Care Unit

Resource links provided by NLM:

Further study details as provided by St. John Health System, Michigan:

Primary Outcome Measures:
  • A significantly higher incidence of a rescue free laxation with methylnaltrexone within 4 hours +- 45 minutes. [ Time Frame: Nine months ]

Secondary Outcome Measures:
  • Decreased need for rescue medications to have a bowel movement in the treatment arm vs placebo. [ Time Frame: Nine months ]

Estimated Enrollment: 80
Study Start Date: December 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Methylnaltrexone Bromide Drug: Methylnaltrexone Bromide
The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
Other Name: Relistor
Placebo Comparator: Placebo Drug: Placebo-Normal Saline
Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
Other Name: Relistor


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older in the ICU
  • Opioids for analgesia for at least 24 hours.
  • Opioid-induced constipation with no bowel movement within the last 72 hours.
  • Women of childbearing potential had negative pregnancy tests.

Exclusion Criteria:

  • Contraindication to use of the GI tract
  • Diarrhea on admission
  • Bowel surgery within 8 weeks of admission
  • Ileostomy or colostomy
  • Not expected to live or stay more than 3 days in the intensive care unit
  • Constipation that was not primarily caused by opioids (as determined by the investigator)
  • No opioid use in the last 24 hours,
  • Mechanical gastrointestinal obstruction
  • An indwelling peritoneal catheter
  • Clinically active diverticular disease
  • Fecal impaction
  • Acute surgical abdomen
  • History of Crohn's disease or ulcerative colitis
  • On Palliative care
  • Less than 18 years old
  • Bowel movement in last 72 hours.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01050595

Contact: Bradford A Whitmer, D.O. 2482891272

United States, Michigan
Providence Hospital and Medical Center Recruiting
Southfield, Michigan, United States, 48075
Contact: Lynne C Paul, Rn, MSN    248-849-5805   
Contact: Nicole D Bolda    248-849-889   
Principal Investigator: Bradford A Whitmer, DO         
Sponsors and Collaborators
St. John Health System, Michigan
Principal Investigator: Bradford A Whitmer, D.O. Providence Hospital and Medical Center
  More Information


Responsible Party: Bradford Whitmer, DO, Providence Medical Center and Hospital Identifier: NCT01050595     History of Changes
Other Study ID Numbers: 107199
Study First Received: January 13, 2010
Last Updated: January 13, 2010

Keywords provided by St. John Health System, Michigan:
Intensive Care Unit
Bowel Management

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on September 18, 2017